Hodgkin Lymphoma (Adults)

Disease Study # Study Title and Description PI
Relapsed/Refractory E4412-CIRB A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma Anne Beaven, MD
Relapsed LCCC1524-ATL Phase I Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Prevention of Relapse of CD30+ Lymphomas After High Dose Therapy and Autologous Stem Transplantation (ATLAS) Thomas Shea, MD
Relapsed LCCC1606-ATL Phase I Study of the Administration of T lymphocytes Co-Expressing the CD30 Chimeric Antigen Receptor (CAR) and CCR4 for Relapsed/Refractory CD30+ Hodgkin Lymphoma and CD30+ Non-Hodgkin Lymphoma Natalie Grover, MD
Relapsed (HIV) AMC-095 A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin Lymphoma Michael Lee, MD

Hodgkin Lymphoma (Pediatrics)

Disease Study # Study Title and Description PI
Relapsed AHOD1721-CA209744 Risk-Based, Response-Adapted, Phase II Open-Label Trial of Nivolumab + Brentuximab Vedotin (N + Bv) for Children, Adolescents, and Young Adults with Relapsed/Refractory (R/R) CD30 + Classic Hodgkin Lymphoma (cHL) After Failure of First-Line Therapy, Followed by Brentuximab + Bendamustine (Bv + B) for Participants with a Suboptimal Response. Checkmate 744 Stuart Gold MD
Relapsed LCCC1532-ATL Phase Ib/II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Hodgkin’s Lymphoma and CD30+ Non-Hodgkin’s Lymphoma Anne Beaven, MD
Relapsed LCCC1524-ATL Phase I Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Prevention of Relapse of CD30+ Lymphomas After High Dose Therapy and Autologous Stem Transplantation (ATLAS) Thomas Shea, MD
Frontline AHOD1331 A Randomized Phase III Study of Brentuximab vedotin (IND #117117) for Newly Diagnosed Classical Hodgkin Lymphoma (cHL) in Children and Adolescents Stuart Gold MD

Non-Hodgkin Lymphoma (Multiple Subtypes)

Disease Study # Study Title and Description PI
Relapsed/Refractory LCCC1813-ATL A Phase I Study of Autologous Activated T-cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch in Subjects with Relapsed/Refractory B-cell Lymphoma Natalie Grover, MD

Mantle Cell Lymphoma

Disease Study # Study Title and Description PI
Frontline EA4151-CIRB A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission Anne Beaven, MD

Diffuse large B-cell lymphoma (DLBCL)

Disease Study # Study Title and Description PI

Frontline

AMC-101 A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas (ARL) Christopher Dittus, DO, MPH

Any (HIV)

AMC-083 Tissue Acquisition for Analysis of Prognostic Factors, Immunology, and Genetic Progression of HIV-1 Associated Malignancies Christopher Dittus, DO, MPH

Frontline

GO39942 A Phase III, Multicenter, Randomized,Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination with Rituximab and CHP (R-CHP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma Natalie Grover, MD

T-Cell Lymphoma

Disease Study # Study Title and Description PI

Frontline

LCCC1637

Brentuximab Vedotin with Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (BV-CHEP) for the treatment of Adult T-Cell Leukemia/Lymphoma: A Phase II Trial of the Rare Lymphoma Working Group Christopher Dittus, DO, MPH
Relapsed LCCC1524-ATL Phase I Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Prevention of Relapse of CD30+ Lymphomas After High Dose Therapy and Autologous Stem Transplantation (ATLAS) Thomas Shea, MD
Relapsed LCCC1532-ATL Phase Ib/II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Hodgkin’s Lymphoma and CD30+ Non-Hodgkin’s Lymphoma Anne Beaven, MD
Relapsed LCCC1606-ATL Phase I Study of the Administration of T lymphocytes Co-Expressing the CD30 Chimeric Antigen Receptor (CAR) and CCR4 for Relapsed/Refractory CD30+ Hodgkin Lymphoma and CD30+ Non-Hodgkin Lymphoma Natalie Grover, MD

Cutaneous T-Cell Lymphoma

Disease Study # Study Title and Description PI
Relapsed LCCC1606-ATL Phase I Study of the Administration of T lymphocytes Co-Expressing the CD30 Chimeric Antigen Receptor (CAR) and CCR4 for Relapsed/Refractory CD30+ Hodgkin Lymphoma and CD30+ Non-Hodgkin Lymphoma Natalie Grover, MD

EBV-Positive Lymphomas

Disease Study # Study Title and Description PI

Relapsed

EBV-CTL-201

Multicenter Expanded Access Protocol of Allogeneic Epstein-Barr Virus Cytotoxic T Lymphocytes (EBV-CTLs) for Patients with EBV-Associated Lymphomas and Lymphoproliferative Disorders in Immunocompromised Patients for Whom There are No Other Comparable Option Marcie Riches, MD, MS

 

Search for Clinical Trials